| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T381 |
0-106 |
Sentence |
denotes |
As has already been demonstrated for autoimmune patients, HCQ demonstrated great anti-diabetic properties. |
| T382 |
107-452 |
Sentence |
denotes |
The first proofs of the role of HCQ in glucose and insulin homeostasis date back to 1999, when Emami, Gerstein, Pasutto, and Jamali [105] demonstrated that diabetic rats treated with oral doses of 80, 120, and 160 mg/kg/day of HCQ exhibited a dose-dependent increase in insulin blood levels, with a consequent reduction of glucose concentration. |
| T383 |
453-705 |
Sentence |
denotes |
Higher doses of HCQ (200 mg/kg/day) were tested by Abdel-Hamid, A.A. and El-Firgany Ael, D. [106] on diabetic rats, finding an HCQ-mediated decrease in the pancreas, as the mechanism underlying the improvement of the metabolic profile in diabetic rats. |
| T384 |
706-892 |
Sentence |
denotes |
The same authors associated the beneficial impact of HCQ on insulin resistance in diabetic rats with its ability to restore adipokine balance and reduce endothelial stress markers [113]. |
| T385 |
893-1034 |
Sentence |
denotes |
Given the positive outcomes deriving from preclinical studies, the therapeutic potential of HCQ was also assessed in several clinical trials. |
| T386 |
1035-1159 |
Sentence |
denotes |
Included in a randomized, double-blinded study of 18 months with 300 mg of HCQ twice a day were 135 diabetic obese patients. |
| T387 |
1160-1323 |
Sentence |
denotes |
HCQ treatment improved glycemic control, as demonstrated by the decrease of glycated hemoglobin by up to 1% respect to the placebo, without any side effects [107]. |
| T388 |
1324-1560 |
Sentence |
denotes |
An open-label longitudinal study engaging 13 obese non-diabetic individuals examined the effects of a dose of 6.5 mg/kg/day of HCQ for six weeks, demonstrating a significant reduction in insulin resistance, assessed by HOMA index [108]. |
| T389 |
1561-1750 |
Sentence |
denotes |
In a randomized, double-blinded, controlled trial on 39 prediabetic subjects, the effect of 12-week treatment with 6.5 mg/kg/day of HCQ on glycemic status and lipidic profile was evaluated. |
| T390 |
1751-1901 |
Sentence |
denotes |
Results reported a significant increase in insulin levels, demonstrating the potential use of HCQ to counteract the risk of developing diabetes [109]. |
| T391 |
1902-2110 |
Sentence |
denotes |
A randomized double-blind study involving 267 type-2 diabetic patients compared the efficacy of HCQ (400 mg/day) and pioglitazone, a common anti-diabetic drug, in the control of glycemic and lipidic profiles. |
| T392 |
2111-2305 |
Sentence |
denotes |
No statistically significant differences emerged between the two medicines in terms of glycated hemoglobin and glucose levels, although both drugs produced an improvement in glycemic parameters. |
| T393 |
2306-2408 |
Sentence |
denotes |
Regarding lipidic status, total cholesterol and LDL levels were reduced more by HCQ than pioglitazone. |
| T394 |
2409-2527 |
Sentence |
denotes |
Given the good tolerability of the treatment, HCQ may arise as a therapeutic alternative in diabetes management [110]. |
